TWST insider sales: 6,888 shares vesting; Leproust sold 7,205 and 8,061 shares (TWST)
Twist Bioscience Corp (TWST) filed a Form 144 to sell 6,888 shares of common stock stemming from restricted stock vesting on May 20, 2026. The filing also detailed several past sales by Emily M. Leproust, including 7,205 shares on February 23, 2026, and 8,061 shares on April 22, 2026. This activity represents routine insider disclosures related to stock vesting and prior open-market dispositions.
Twist Bioscience (NASDAQ: TWST) insider files to sell 688 shares
A Twist Bioscience (NASDAQ: TWST) insider has filed a Form 144 to sell 688 shares of common stock through Fidelity Brokerage Services LLC, with an execution date noted as May 21, 2026. The filing also disclosed four previous open-market dispositions by Robert F. Werner, totaling 6,064 shares between February and May 2026. These transactions are routine insider dispositions under resale/affiliate rules, with the proposed sale originating from restricted stock vesting.
TWST (NASDAQ: TWST) proposed sale of 4,160 common shares (Form 144)
The article details a Form 144 filing by Twist Bioscience Corp (NASDAQ: TWST) regarding a proposed sale of 4,160 common shares following a restricted stock vesting event on May 20, 2026. The filing also reports past sales by Patrick Finn on three different dates in early 2026. Fidelity Brokerage Services LLC is listed as the broker/dealer for the proposed sale.
Twist Bioscience Corp stock (US90130A1016): biotech shares under pressure despite fresh AI drug disc
Twist Bioscience Corp shares experienced a pullback after a strong rally, despite the company announcing a new AI-driven drug discovery partnership with LenioBio. The article delves into the company's core business model of synthetic DNA manufacturing, its revenue drivers, and how recent developments, including the new partnership, fit into the broader market sentiment. It concludes by highlighting the strategic importance of Twist Bioscience at the intersection of genomics, synthetic biology, and AI, while also noting the stock's sensitivity to market sentiment due to its ongoing operating losses.
Twist Bioscience Corporation - Common Stock (NQ: TWST)
This article provides recent news headlines for Twist Bioscience Corporation (TWST), including financial results, investigative alerts from law firms regarding potential securities fraud, and various corporate announcements. The news covers partnerships, new product launches, leadership promotions, and upcoming conference presentations, predominantly from late 2022. Several law firms are investigating claims against Twist Bioscience Corp, while the company also reported fiscal Q4 and full-year 2022 financial results and addressed a misleading short-seller report.
Understanding Momentum Shifts in (TWST)
This article analyzes Twist Bioscience Corporation (TWST) using AI models to identify momentum shifts. It highlights weak near and mid-term sentiment potentially challenging a long-term positive outlook, and details three trading strategies: Position Trading, Momentum Breakout, and Risk Hedging, with specific entry, target, and stop-loss zones. The analysis also provides multi-timeframe signal strengths and support/resistance levels.
Twist Bioscience (TWST) price target increased by 20.55% to 64.90
This article reports that the price target for Twist Bioscience (TWST) has been increased by 20.55% to $64.90. This adjustment indicates a positive outlook from analysts or market sentiment regarding the company's future performance. However, the provided content is minimal, offering only the headline and published time information.
Have Insiders Sold Twist Bioscience Shares Recently?
A VP & Chief Accounting Officer at Twist Bioscience (NASDAQ:TWST) recently sold US$282k worth of stock, reducing their total holding by 9.1%. This follows a larger sale of US$2.1m by the Senior Vice President of Human Resources during the last year when the share price was lower. Despite these sales, insider ownership remains around 2.4%, and the article suggests caution due to the selling activity and identified warning signs.
Twist Bioscience director Jan Johannessen sells $673,440 in stock
Twist Bioscience director Jan Johannessen sold 12,000 shares of company stock for $673,440 on May 12, 2026, while concurrently exercising options to acquire 12,000 shares. This transaction follows an 84% surge in Twist Bioscience shares over the past year and comes after the company reported strong Q2 2026 revenue growth but an EPS miss. TD Cowen maintained a Buy rating and raised its price target for the stock, citing confidence in revenue achievements despite the EPS shortfall.
Twist Bioscience (TWST) price target increased by 20.55% to 64.90
This article reports a significant positive revision in the price target for Twist Bioscience (TWST). Analysts have increased the target by 20.55% to $64.90. The content implies that this adjustment reflects a more optimistic outlook on the company's stock performance.
Twist Bioscience director Jan Johannessen sells $673,440 in stock By Investing.com
Twist Bioscience director Jan Johannessen sold 12,000 shares of the company's common stock for $673,440 on May 12, 2026, while also exercising options to acquire 12,000 shares for $168,000. The stock sale occurred despite a significant 84% surge in share price over the past year, though InvestingPro analysis suggests the stock is currently overvalued. This transaction follows the company's recent Q2 2026 earnings report, which showed robust revenue growth but an EPS miss, leading TD Cowen to raise its price target to $68 with a Buy rating.
Twist Bioscience director Jan Johannessen sells $673,440 in stock By Investing.com
Twist Bioscience director Jan Johannessen sold 12,000 shares of common stock for $673,440 on May 12, 2026, while simultaneously acquiring 12,000 shares through employee stock options for $168,000. The sale occurred as the stock had surged 84% over the past year, though InvestingPro indicated it is overvalued. The company recently reported robust revenue growth but missed EPS targets for Q2 fiscal year 2026, leading TD Cowen to raise its price target to $68 with a Buy rating.
Twist Bioscience (TWST) director exercises options and sells 12,000 shares
Twist Bioscience Corp director Jan Johannessen exercised employee stock options for 12,000 shares at $14.00 per share, increasing his holdings before the sale. On the same day, he sold these 12,000 common shares at an average price of $56.12 per share, resulting in a net sale of $673,440. After these transactions, Johannessen's direct holdings in Twist Bioscience are 17,754 shares.
Twist Bioscience Corp stock (US90130A1016): revenue keeps rising as Cathie Wood trims position
Twist Bioscience Corp (TWST) has reported its 13th consecutive quarter of sequential revenue growth in fiscal Q2 2026, with revenue reaching $110.7 million, up 19% year over year. Despite this growth and improving gross margins, the company remains unprofitable on an adjusted EBITDA basis, though losses are narrowing. High-profile investor Cathie Wood has trimmed her position after a significant share price increase, and elevated short interest indicates a divided market outlook.
Have Insiders Sold Twist Bioscience Shares Recently?
Twist Bioscience Corporation insiders have recently sold shares, with the VP & Chief Accounting Officer selling US$282k worth of stock and the Senior Vice President of Human Resources selling US$2.1m over the last year. Despite these sales, the company has seen no insider purchases in the last year. Insider ownership remains moderate at 2.4%, prompting caution regarding the company's stock from an insider transaction perspective.
Twist Bioscience chief accounting officer sells $282,186 in stock
Twist Bioscience chief accounting officer, Robert F. Werner, sold 4,961 shares of company stock for $282,186 on May 8, 2026, with the stock trading near its 52-week high after a significant gain. This transaction occurred shortly after the company reported strong Q2 2026 revenue growth but an EPS miss, leading TD Cowen to raise its price target while maintaining a Buy rating.
Twist Bioscience (TWST) CAO sells 4,961 shares in open-market trade
Twist Bioscience's Chief Accounting Officer, Robert F. Werner, sold 4,961 shares of Common Stock at $56.881 per share in an open-market transaction on May 8, 2026. Following this sale, Werner still directly holds 49,674 shares of Twist Bioscience. This transaction was reported via a Form 4 SEC filing and is considered a routine-sized sale by an insider with substantial remaining equity holdings, resulting in a moderate negative filing impact.
Twist Bioscience Corp SEC Filing
A Form 144 Notice of Proposed Sale of Securities was filed by Twist Bioscience Corp (TWST) on May 12, 2026. The filing indicates a sale of 12,000 shares of common stock with an aggregate market value of $673,440.00, acquired via option grant on October 30, 2018. The sale is to be executed through Fidelity Brokerage Services LLC on NASDAQ.
UBS Group AG Acquires 147,389 Shares of Twist Bioscience Corporation $TWST
UBS Group AG increased its stake in Twist Bioscience Corporation by 28.6% in the fourth quarter, acquiring an additional 147,389 shares to bring its total holdings to 662,317 shares valued at $21.0 million. Wall Street analysts maintain a "Moderate Buy" consensus rating with an average price target of $56.57, while the company reported mixed Q4 results, with revenue beating expectations but EPS missing estimates. Insider activity shows recent share sales by the CEO and a Director.
Number of shareholders of Twist Bioscience Corp. – MIL:1TWST
This article provides the stock symbol and exchange information for Twist Bioscience Corp. (1TWST) on Euronext Milan. It confirms the availability of financial data, news, and community discussions for the company through TradingView. The page focuses on offering an overview of shareholder numbers, though specific figures are not included in the provided text.
TWST (TWST) affiliate Robert F. Werner reports three small resales
An SEC Form 144 filing indicates that Robert F. Werner, an affiliate of Twist Bioscience Corp (TWST), reported three small share resales in early 2026, totaling 2,103 shares for gross proceeds of $99,872.95. The filing also listed several future Restricted Stock Vesting events. These transactions are considered routine and neutral in impact, given their small size relative to the company's overall stock performance.
LenioBio and Twist Bioscience Enter into a Collaboration to Further Enable AI drug-discovery
LenioBio and Twist Bioscience have announced a collaboration to accelerate AI-driven drug discovery. This partnership will integrate LenioBio's ALiCE® cell-free protein expression platform with Twist's DNA manufacturing to speed up the design-build-test cycle for protein expression services. The goal is to provide rapid, high-quality experimental data to feed back into AI models, improving the efficiency and accuracy of new protein molecule design for biologic drugs.
LenioBio and Twist Bioscience Enter into a Collaboration to Further Enable AI drug-discovery
LenioBio and Twist Bioscience have partnered to integrate LenioBio's ALiCE® cell-free protein expression platform with Twist's DNA manufacturing and automation capabilities. This collaboration aims to accelerate the design-build-test cycle for protein expression services, providing faster experimental results to AI models for drug discovery. The goal is to improve the speed and quality of data generation, particularly for complex eukaryotic proteins, thereby enhancing AI-driven protein and antibody design.
Twist Bioscience Corp (TWST) Climbed on Earnings Beat
Twist Bioscience Corporation (TWST) was highlighted by Artisan Mid Cap Fund as a top contributor in Q1 2026, with the company's recent results exceeding expectations in revenue and gross margin. TWST's shares have significantly increased over the past year, and the company raised its full-year revenue guidance while confirming adjusted EBITDA breakeven in fiscal Q4 2026. The company is experiencing increased demand for its synthetic DNA products from pharmaceutical and AI-driven customers, positioning it for continued market share gains.
William Blair LLC discloses 8.6% stake in Twist Bioscience (NASDAQ: TWST)
William Blair Investment Management, LLC has filed an Amendment No. 2 to a Schedule 13G/A, reporting a beneficial ownership of 5,269,718 shares of Twist Bioscience (NASDAQ: TWST), which represents 8.6% of the company's common stock. The firm holds sole voting power over 4,836,983 shares and sole dispositive power over all 5,269,718 shares. This filing indicates a passive investment intent and updates previous disclosures.
Twist Bioscience SVP Cho sells $112,125 in shares
Dennis Cho, SVP at Twist Bioscience Corp (NASDAQ:TWST), sold 1,962 shares totaling $112,125. This sale was a "sell to cover" transaction to fulfill tax withholding obligations related to Restricted Stock Units, not a discretionary trade. The company recently reported Q2 FY2026 revenues of $111 million, exceeding estimates, but an EPS of -$0.71, missing forecasts.
Twist Bioscience releases quarterly results, investor call today
Twist Bioscience Corporation announced its financial results and business highlights for the second quarter of fiscal year 2026, which ended on March 31, 2026. The company will host a conference call and live audio webcast for analysts and investors to discuss these results and provide business updates at 8:00 a.m. Eastern Time today. The detailed earnings report and investor presentation are available on the company's investor relations website.
Twist Bioscience Corporation Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Twist Bioscience Corporation (NASDAQ: TWST) announced inducement grants totaling 115,279 equity awards to 53 newly hired individuals. These awards, comprising restricted stock units (RSUs) and performance stock units (PSUs), are a material inducement for their employment under Nasdaq Listing Rule 5635(c)(4). The RSUs vest over 48 months, while the PSUs are tied to specific performance metrics to be achieved by the end of the 2027 fiscal year.
Twist Bioscience CAO Robert Werner sells $9,372 in stock
Robert F. Werner, CAO of Twist Bioscience (NASDAQ:TWST), sold 164 shares worth $9,372 on May 4, 2026, to cover tax withholding from Restricted Stock Units. This transaction was not discretionary and still leaves him with 54,635 shares. The sale occurred as TWST shares have risen 73% over the past year, and the company recently reported strong Q2 2026 revenues of $111 million, despite an EPS miss.
Twist Bioscience president, COO Finn sells $162,531 in stock
Patrick John Finn, President and COO of Twist Bioscience Corp, sold 2,844 shares worth approximately $162,531 to cover tax withholding obligations associated with Restricted Stock Unit vesting, not as a discretionary trade. Following the sale, Finn directly owns 278,964 shares. The company recently reported strong Q2 2026 revenue of $111 million, beating estimates, though EPS missed expectations.
Twist Bioscience (TWST) COO sells 2,844 shares to cover RSU tax
Twist Bioscience's President and COO, Patrick John Finn, sold 2,844 shares of common stock at an average price of $57.1488 per share. This transaction was a "sell to cover" to fulfill tax withholding obligations tied to the vesting of Restricted Stock Units, as mandated by the company's equity incentive plans, and not a discretionary sale. After this sale, Finn still directly holds 278,964 shares of Twist Bioscience stock.
Twist Bioscience (TWST) officer sells 1,962 shares to cover RSU taxes
Dennis Cho, an officer at Twist Bioscience (TWST), sold 1,962 shares of company stock on May 4, 2026, at $57.1488 per share. This transaction was a mandated "sell to cover" to satisfy tax withholding obligations related to vesting Restricted Stock Units, not a discretionary trade. After the sale, Cho directly holds 135,941 shares of Twist Bioscience common stock.
Twist Bioscience (NASDAQ: TWST) CAO sell-to-cover RSU tax shares
Twist Bioscience's Chief Accounting Officer, Robert F. Werner, sold 164 shares of common stock at $57.1488 per share on May 4, 2026. This transaction was a "sell-to-cover" sale mandated by the company's equity incentive plan to satisfy tax withholding obligations related to vesting Restricted Stock Units (RSUs) and was not a discretionary trade. Following this sale, Werner directly owns 54,635 shares of Twist Bioscience common stock.
Twist Bioscience SVP Cho sells $112,125 in shares
Dennis Cho, SVP at Twist Bioscience Corp, sold 1,962 shares worth $112,125 to cover tax withholding on restricted stock units, not as a discretionary trade. This transaction follows the company's Q2 FY2026 earnings, which showed a 19% revenue increase to $111 million but an EPS miss of -$0.71. Despite the earnings shortfall, analyst TD Cowen raised its price target for TWST from $58 to $68, maintaining a Buy rating.
Twist offers 115,279 stock awards to 53 new hires under Nasdaq rule
Twist Bioscience Corporation announced it will grant a total of 115,279 inducement equity awards to 53 new hires. These awards, consisting of restricted stock units (RSUs) and performance stock units (PSUs), are made under Nasdaq Listing Rule 5635(c)(4) to attract new talent. The RSUs vest over 48 months, while the PSUs vest based on performance metrics to be achieved by the end of the 2027 fiscal year.
Twist Bioscience Corporation Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - May 5, 2026
Twist Bioscience Corporation announced inducement grants under NASDAQ Listing Rule 5635(c)(4), consisting of 115,279 equity awards granted to 53 recently hired individuals. These awards include 101,931 restricted stock units (RSUs) and up to 13,348 performance stock units (PSUs), serving as material inducements for their employment. The RSUs vest over 48 months, while PSUs are tied to performance metrics to be achieved by the end of fiscal year 2027.
Twist Bioscience Corporation (NASDAQ:TWST) Q2 2026 Earnings Call Transcript
Twist Bioscience Corporation reported strong Q2 2026 results with a 19.3% year-over-year revenue growth, reaching $110.7 million, marking their 13th consecutive quarter of sequential growth. The company saw significant acceleration in its DNA synthesis and Protein Solutions segment, particularly driven by AI-enabled drug discovery, and anticipates improved sequential growth in its NGS applications in the latter half of the fiscal year. Twist Bioscience remains on track to achieve adjusted EBITDA breakeven in Q4 2026, benefiting from gross margin expansion, operating expense discipline, and strategic investments in capacity and automation.
Twist Bioscience Corporation Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Twist Bioscience Corporation (NASDAQ: TWST) has announced inducement grants totaling 115,279 equity awards to 53 newly hired individuals. These awards, consisting of restricted stock units (RSUs) and performance stock units (PSUs), are a material inducement for their employment under Nasdaq Listing Rule 5635(c)(4) and vest over 36-month periods. The inducement plan aims to attract new talent by offering equity awards to individuals not previously employed by Twist.
Twist Bioscience (TWST) Reports 19.3% Revenue Growth in Q2 Fisca
Twist Bioscience (TWST) announced a 19.3% year-over-year revenue increase in Q2 fiscal 2026, driven by strong performance in AI-driven drug discovery and DNA Synthesis. The company achieved a gross margin of 51.6% and raised its fiscal 2026 revenue guidance to $442 million to $447 million. Despite insider selling, its high GF Score™ and Growth Rank suggest strong future potential, though profitability remains a challenge.
Revenue climbs at Twist Bioscience (NASDAQ: TWST) as losses and cash burn persist
Twist Bioscience (NASDAQ: TWST) reported a 19% revenue increase to $110.7 million for the quarter ended March 31, 2026, driven by strong growth in DNA synthesis and protein solutions, and NGS applications. Despite improved gross margins of 51.6%, the company remains unprofitable, with a quarterly net loss of $44.0 million and a six-month loss of $74.5 million, due to increased operating expenses and $7.2 million in litigation settlement costs. Twist Bioscience ended the quarter with $171.7 million in cash, cash equivalents, and short-term investments, which is expected to fund operations for at least one year.
AI-Driven Demand Boosts Twist Bioscience Sales, But Loss Widens
Twist Bioscience reported stronger-than-expected sales growth, especially in its DNA Synthesis and Protein Solutions and NGS Applications segments, driven by AI-enabled drug discovery. Despite increased revenue and an optimistic outlook on achieving adjusted EBITDA breakeven by Q4 fiscal 2026, the company missed consensus earnings estimates and saw its loss widen due to litigation settlement costs. The company also raised its fiscal 2026 sales guidance and expanded its clonal genes portfolio.
Twist Bioscience Announces Fiscal 2026 Second Quarter Financial Results
Twist Bioscience Corporation (NASDAQ: TWST) announced its financial results and business highlights for the second quarter of fiscal year 2026, which ended on March 31, 2026. The company will host a conference call and live audio webcast for analysts and investors to discuss these results and provide a business update. A detailed report and investor presentation are available on their investor relations website.
TWIST BIOSCIENCE ($TWST) Releases Q2 2026 Earnings
TWIST BIOSCIENCE ($TWST) announced its Q2 2026 earnings, reporting an EPS of -$0.62, missing analyst estimates, but revenue of $110.72 million, which beat expectations. Insider trading primarily shows sales, while hedge fund activity is mixed, with some major institutions adding and others reducing their positions. Analysts have provided price targets for TWST, with a median target of $55.0.
Twist Bioscience: Fiscal Q2 Earnings Snapshot
Twist Bioscience Corp. reported a fiscal second-quarter loss of $44 million, or 71 cents per share, which adjusted to 62 cents per share. The company's revenue for the period was $110.7 million, exceeding analyst forecasts of $107.8 million. Twist Bioscience anticipates Q3 revenue between $114 million and $115 million, and full-year revenue ranging from $442 million to $447 million.
Twist Bioscience: Fiscal Q2 Earnings Snapshot
Twist Bioscience Corp. (TWST) reported a fiscal second-quarter loss of $44 million, translating to 71 cents per share, or an adjusted loss of 62 cents per share. The company, a synthetic DNA maker, exceeded revenue forecasts with $110.7 million, surpassing the $107.8 million expected by analysts. Twist Bioscience provided revenue guidance of $114 million to $115 million for the current quarter and $442 million to $447 million for the full year.
Twist Bioscience (NASDAQ: TWST) lifts FY26 outlook after 19% Q2 growth
Twist Bioscience (NASDAQ: TWST) reported strong Q2 FY26 results with record revenue of $110.7 million, a 19% increase year-over-year, and improved gross margin to 51.6%. Despite continued net losses due to higher operating costs and a $7.2 million litigation settlement, the company raised its full-year 2026 revenue guidance to $442-$447 million and reaffirmed its target of achieving adjusted EBITDA breakeven in Q4 FY26. This performance marks the 13th consecutive quarter of sequential growth for Twist Bioscience.
Twist Bioscience Expands Clonal Genes Offering to Include Long and Complex Sequences
Twist Bioscience has expanded its clonal genes portfolio with the early access launch of "Complex Genes," enabling the synthesis and delivery of long and structurally complex DNA sequences up to 7,000 base pairs. This expansion aims to support advancements in nucleic acid therapeutics and AI-enabled drug discovery by reliably providing previously difficult-to-produce complex sequences at scale, significantly increasing the acceptance rate for customer orders. The company emphasizes its ability to synthesize elements like short tandem, inverted, and long repeats, as well as high or low GC content, for faster iteration and accelerated discovery timelines.
Pictet Asset Management Holding SA Grows Holdings in Twist Bioscience Corporation $TWST
Pictet Asset Management Holding SA significantly increased its stake in Twist Bioscience Corporation ($TWST) by 108.5% in Q4, acquiring an additional 115,880 shares. This brings their total holding to 222,647 shares, valued at approximately $7.3 million. Despite several analysts raising price targets and a consensus "Moderate Buy" rating, the company remains unprofitable with a negative net margin, and insiders have recently sold shares.
TWST - Twist Bioscience Corp Stock Price and Quote
This page provides detailed stock information for Twist Bioscience Corp (TWST), including its current stock price, financial metrics, recent news, analyst ratings, and insider trading activity. The company's stock closed at $56.19, down 6.97%, and a recent headline notes a $17.1M agreement in principle to settle a securities class action. Various officers and directors have engaged in stock sales and option exercises in early 2026.
Twist Bioscience faces earnings test as breakeven path looms
Twist Bioscience (TWST) is reporting its fiscal second-quarter results, with analysts expecting a $0.48 per share loss on $107.7 million in revenue. Investors will be focused on the company's progress towards adjusted EBITDA breakeven by year-end 2026, potential revenue from new partnerships like Amazon's Bio Discovery platform, and whether operating leverage is improving to narrow losses without hindering new DNA synthesis investments. The report comes after the company previously raised its full-year 2026 revenue guidance to $435-$440 million.
